Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

NCT01271283 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia

Interventions

OTHER: Diagnostic Laboratory Biomarker Analysis
DRUG: Lenalidomide

Sponsor

National Cancer Institute (NCI)